Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor

Molecular Therapy

Volumn 20, Issue 2, 2012, Pages 391-397

  Nimjee, Shahid M ^a,b   Lohrmann, Jens D ^a,b   Wang, Haichen ^a   Snyder, David J ^a   Cummings, Thomas J ^a   Becker, Richard C ^a,b   Oney, Sabah ^a,b,c   Sullenger, Bruce A ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; APTAMER; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN CONTAINING POLYCATION; OLIGONUCLEOTIDE; POLYCATION; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CH 9.14 T10 APTAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLEEDING; BLOOD FLOW; CAROTID ARTERY INJURY; COMBINATION CHEMOTHERAPY; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DESIGN; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL SURGERY; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; THROMBOCYTE FUNCTION; THROMBOSIS; THROMBOSIS PREVENTION;

ANIMALIA; MURINAE;

EID: 84856555599     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.226     Document Type: Article

References (29)

1. Conway, DS, Pearce, LA, Chin, BS, Hart, RG and Lip, GY (2003). Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107: 3141-3145. (Pubitemid 36793082)
2. Kamphuisen, PW, Eikenboom, JC and Bertina, RM (2001). Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21: 731-738. (Pubitemid 32448761)
3. Cosmi, B (2009). ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr Opin Mol Ther 11: 322-328.
4. Diener, JL, Daniel Lagassé, HA, Duerschmied, D, Merhi, Y, Tanguay, JF, Hutabarat, R et al. (2009). Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 7: 1155-1162.
5. Wu, D, Vanhoorelbeke, K, Cauwenberghs, N, Meiring, M, Depraetere, H, Kotze, HF et al. (2002). Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 99: 3623-3628. (Pubitemid 34534531)
6. Yamamoto, H, Vreys, I, Stassen, JM, Yoshimoto, R, Vermylen, J and Hoylaerts, MF (1998). Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost 79: 202-210. (Pubitemid 28037082)
7. Cadroy, Y, Hanson, SR, Kelly, AB, Marzec, UM, Evatt, BL, Kunicki, TJ et al. (1994). Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 83: 3218-3224. (Pubitemid 24158466)
8. Oney, S, Nimjee, SM, Layzer, J, Que-Gewirth, N, Ginsburg, D, Becker, RC et al. (2007). Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17: 265-274. (Pubitemid 47463359)
9. Rusconi, CP, Roberts, JD, Pitoc, GA, Nimjee, SM, White, RR, Quick, G Jr et al. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22: 1423-1428. (Pubitemid 39482862)
10. Westrick, RJ, Winn, ME and Eitzman, DT (2007). Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol 27: 2079-2093. (Pubitemid 350287234)
11. Denis, C, Methia, N, Frenette, PS, Rayburn, H, Ullman-Culleré, M, Hynes, RO et al. (1998). A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 95: 9524-9529. (Pubitemid 28506264)
12. Pergolizzi, RG, Jin, G, Chan, D, Pierre, L, Bussel, J, Ferris, B et al. (2006). Correction of a murine model of von Willebrand disease by gene transfer. Blood 108: 862-869. (Pubitemid 44154618)
13. Oney, S, Lam, RT, Bompiani, KM, Blake, CM, Quick, G, Heidel, JD et al. (2009). Development of universal antidotes to control aptamer activity. Nat Med 15: 1224-1228.
14. Ruggeri, ZM (2003). Von Willebrand factor. Curr Opin Hematol 10: 142-149. (Pubitemid 36207970)
15. Ruggeri, ZM, Dent, JA and Saldívar, E (1999). Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 94: 172-178. (Pubitemid 29300146)
16. Jackson, SP and Schoenwaelder, SM (2003). Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2: 775-789. (Pubitemid 37361810)
17. Gandhi, CD, Johnson, DM and Patel, AB (2007). The endovascular management of intracranial vascular disease including the MERCI device. Curr Treat Options Cardiovasc Med 9: 99-108. (Pubitemid 46831504)
18. Nelson, PK, Sahlein, D, Shapiro, M, Becske, T, Fitzsimmons, BF, Huang, P et al. (2006). Recent steps toward a reconstructive endovascular solution for the orphaned, complex-neck aneurysm. Neurosurgery 59(5 Suppl 3): S77-92; discussion S3.
19. Bendok, BR, Padalino, DJ, Levy, EI, Qureshi, AI, Guterman, LR and Hopkins, LN (2004). Intravenous abciximab for parent vessel thrombus during basilar apex aneurysm coil embolization: case report and literature review. Surg Neurol 62: 304-311. (Pubitemid 39296678)
20. - (1998). Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339: 436-443.
21. Scarborough, RM, Kleiman, NS and Phillips, DR (1999). Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 100: 437-444. (Pubitemid 29362416)
22. Topol, EJ, Byzova, TV and Plow, EF (1999). Platelet GPIIb-IIIa blockers. Lancet 353: 227-231. (Pubitemid 29088046)
23. Gilbert, JC, DeFeo-Fraulini, T, Hutabarat, RM, Horvath, CJ, Merlino, PG, Marsh, HN et al. (2007). First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116: 2678-2686. (Pubitemid 350291240)
24. Mayr, FB, Knöbl, P, Jilma, B, Siller-Matula, JM, Wagner, PG, Schaub, RG et al. (2010). The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 50: 1079-1087.
25. Spiel, AO, Mayr, FB, Ladani, N, Wagner, PG, Schaub, RG, Gilbert, JC et al. (2009). The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 20: 334-340.
26. Wong, I and Lohman, TM (1993). A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci USA 90: 5428-5432. (Pubitemid 23176173)
27. Harrison, P (2005). Platelet function analysis. Blood Rev 19: 111-123. (Pubitemid 39643116)
28. Konstantinides, S, Schäfer, K, Thinnes, T and Loskutoff, DJ (2001). Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 103: 576-583. (Pubitemid 32116244)
29. Fay, WP, Parker, AC, Ansari, MN, Zheng, X and Ginsburg, D (1999). Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 93: 1825-1830. (Pubitemid 29128482)